Lv7
4598 积分 2021-08-24 加入
Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer
14天前
已完结
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry
16天前
已完结
Identification of key immune-related genes and potential therapeutic targets in immune checkpoint inhibitor-associated myocarditis
16天前
已完结
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
16天前
已完结
Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials
17天前
已完结
Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges
19天前
已完结
Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape
19天前
已完结
Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial
19天前
已完结
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy
19天前
已完结
Adjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy
19天前
已完结
皖公网安备34019202002308
